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a b s t r a c t
Cervical cancer is a major global health problem for women. Despite the screening and
vaccines available today, it continues to be the fourth most common cancer in women world-
wide with 85% of cases occurring in developing countries. Standard treatments for early or
locally advanced cervical cancer are surgery (S) or concomitant chemo-radiotherapy (CT-RT).
Neoadjuvant chemotherapy (NACT) prior to surgery or radiotherapy has been proposed and
tested in clinical trials and has been included in clinical practice in some countries.
In order to determine the true role of NACT either prior to S or RT in terms of achiev-
ing benefits in OS or DFS, randomized clinical trials and meta-analyses published from its
beginnings to the present have been searched and analyzed in this study.
The analysis of published clinical trials shows that NACT followed by S and NACT followed
by RT have failed to demonstrate benefits in OS or DFS. Clinical trials comparing NACT
followed by S versus exclusive RT have also been analyzed, where NACT followed by S could
not show benefits for RT either.
Conclusion: Adding neoadjuvant chemotherapy to S or RT cannot be recommended outside
the context of clinical trials.
© 2018 Published by Elsevier Sp. z o.o. on behalf of Greater Poland Cancer Centre.
1. Introduction
Cervical cancer is a major global health problem for women.
Despite the screening and vaccines available today, it con-
tinues to be the fourth most common cancer in women
worldwide1,2 with 85% of cases occurring in developing
countries.3,4 Radiotherapy (RT) and surgery (S) are equally
effective in early stages (FIGO IA-IBI), each giving 5-year
survival rates of around 80–90%.5 Historically, the standard
treatment for IA and IB1 is surgery.6 For more advanced stages
the primary treatment for cervical cancer is either surgery or
E-mail address: marcela.delatorre1@gmail.com
radiotherapy. Even in stages IB2 and II A2 radiotherapy offers
better results than surgery.7 Radical radiotherapy comprises
external beam and intracavitary treatment and is treatment of
choice for locally advanced disease stage IIB, III and IVA offer-
ing an alternative to radical surgery for patients with tumors
larger than 4 cm confined to the cervix (stage IB bulky).8 RT has
also been used for patients not being candidates for hysterec-
tomy. 5-year-survival using radiotherapy ranged from around
60% for patients with stage IIB disease to approximately 20%
for patients with stage IV disease.5
Due to the lack of progress in results during decades of
surgery and radiotherapy and based on the results of cyto-
static agents in patients with disseminated disease, the idea
of incorporating chemotherapy into other strands began to be
reflected in clinical trials.
https://doi.org/10.1016/j.rpor.2018.09.005
1507-1367/© 2018 Published by Elsevier Sp. z o.o. on behalf of Greater Poland Cancer Centre.
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One of the ways to investigate the effect of CT in non-
disseminated cervical cancer patients is as neoadjuvant
treatment to the traditional treatments, that is, to S and/or RT
with the intention of finding out if neoadjuvant chemotherapy
(NACT) could diminish the size of the tumor and thus increase
the operability and/or eradicate the possible micro-metastasis
and/or increase tumor vascularization reducing the number of
hypoxic cells, making the tumor more sensitive to radiation.
Specifically, agents available in early trials were fluorouracil
and hydroxyurea.
In 1981 treatment results of cisplatin as a single agent
chemotherapy for recurrent or metastatic cervix cancer
patients were published.9,10 The showed 50% of response rate
in patients who had received no prior CT and an overall
response rate of 38%.
Given response rates to cisplatin in recurrent or metastatic
cervical cancer patients reported in those times, its use was
tested in 2 neoadjuvant settings: either before S or before RT
as an attempt to improve survival.
2. Neoadjuvant chemotherapy followed by
surgery versus surgery alone
Possible advantages of giving NACT prior to S include the
potential for reducing tumor volume, increasing operability
and helping to control micro-metastatic disease.10–13
Four data base systematic reviews concerning NACT were
published by Cochrane Library (1999, 2004, 2010 and 2012).
Latest version of Cochrane Data Base Systematic Review for
NACT followed by S versus S alone was published in 2012.14
The first published review was published in15 and updated
with more recent searches and additional data in 2012. The
review included six trials16–21 randomized between 107 and
291 women with FIGO stages IB to IIIB from 1987 to 2005. One
trial20 included only women with FIGO IB2 (bulky) disease. Two
trials16,18 recruited women with both IB1 and IB2 disease. Of
the remaining three trials, two19,21 randomized women with
stage IB2 to IIB disease, where most were classed as stage IB
to IIA (66%), and one17 randomized women with stage IB to
IIIB disease, very heterogeneous population. Cisplatin-based
CT was used in all trials, with some variation in the treat-
ment regimens and platinum dose. The type of S varied from
pelvic lymphadenectomy and both pelvic and para-aortic lym-
phadenectomy. Two trials gave RT to patients with inoperable
tumors.16,17 In four trials16,17,20,21 between 36% and 61% of
women who underwent radical hysterectomy also received
post-operative RT. No information was available for one trial19
about how many women had received post-operative RT. All
five of these trials gave post-operative RT (with or without
brachytherapy) to resected patients because of risk factors for
recurrence found at the time of surgery. In one trial,16 100%
of women who underwent radical hysterectomy also received
post-operative RT, regardless of risk factors and they were
clinically stage IB. Trials gave total external beam RT doses
ranging from 45 to 60 Gy in 1.7 to 2.0 Gy fractions, and three
of these also gave brachytherapy in doses ranging from 25 to
60 Gy. Information available from the trial report for one fur-
ther trial21 stated that post-operative pelvic RT consisted of
3 Gy to the entire pelvis and an additional 2 Gy for parametrial
tissue, but it was unclear whether this referred to total dose
or dose per fraction given. In one trial of bulky IB patients,20
radical RT was given to patients both on and off protocol and
furthermore, patients whose disease had progressed beyond
the cervix during NACT were treated with standard CT-RT. Out-
comes of survival and PFS found a significant improvement
with NACT for both. As reported, much more than 50% of the
patients analyzed received RT. The impact of this treatment
is not analyzed and the toxicity of receiving all three treat-
ments is not reported. A significant benefit with NACT was
observed in terms of reduced local recurrence rates, but not for
distant recurrence. It is not possible to attribute this reduction
in local recurrences solely to the administration of NACT, par-
ticularly since a proportion of patients in all trials also received
post-operative RT. Neither is an intention to treat results anal-
ysis performed. However, the conclusions were: both OS and
PFS were improved with NACT. Although the effects were less
clear on all other pre-specified outcomes, they all tended to
be in favor of NACT. Whilst these results appear to indicate
that NACT may offer a benefit over S alone for women with
early-stage or locally advanced cervical cancer, the evidence
is based on only a small number of trials, and further research
may be warranted.
In the same year, Gong et al.22 published a retrospective
clinical study comparing NACT-S versus S alone. Data were
analyzed from 414 patients stage IB2-IIB who underwent treat-
ment between January 2008 and November 2009. The 2-year
progression free survival rates were 93% and 95% in the NACT-
S group, and 94.5% and 97% in the S group (p > 0.05). The
conclusion was that NACT-S did not show a significant advan-
tage for patients with locally advanced cervical cancer.
In 2013, Kim et al.23 published a review on articles
published between January 2007 and September 2010. 5
randomized controlled trials and 4 observational studies
involving 1784 patients out of 523 potentially relevant stud-
ies were included. Overall and loco-regional recurrences and
progression-free survival rates were not different between the
2 treatments. On the other hand, NACT before S was asso-
ciated with poorer overall survival in observational studies
when compared with primary surgical treatment (HR, 1.68;
95% CI, 1.12–2.53). Conclusion of the study was that although
NACT before S reduced the need for adjuvant RT by decreas-
ing tumor size and lymph node metastasis, it failed to improve
survival when compared with primary S in patients with FIGO
stage IB1 to IIA cervical cancer. It should be mentioned that the
criteria for the indication of adjuvant RT are not mentioned
and that at the time of the study they were not standardized
as they are at present.
The results of all these studies are very difficult to com-
pare with the results of the currently standard treatments
because they are small series, with very short follow-up and
unclear selection criteria. However, none showed a significant
advantage with NACT.
More than 50% of operated patients received subsequent
RT. This represented a significant morbidity and a substantial
increase in the cost of treatment without significant bene-
fits.
GOG started a randomized trial in patients with bulky stage
IB cervical cancer comparing NACT followed by radical hys-
terectomy and pelvic/para-aortic lymphadenectomy versus
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radical hysterectomy and pelvic/para-aortic lymphadenec-
tomy. The study was closed early because of slow accrual.
Nevertheless, they concluded that: for patients bulky IB
(≥4 cm) that undergo radical hysterectomy, approximately 50%
will require adjuvant radiation; NACT followed by radical
hysterectomy did not improve PFS or OS as compared to rad-
ical hysterectomy alone and the GOG recommends, based on
this study, against NACT for patients with stage IB2 cervical
cancer.24
Due to all the data presented and in accordance with the
meta-analyses and the published reviews, adding NACT to S
cannot be recommended outside the context of clinical trials.
3. Neoadjuvant chemotherapy followed by
RT
Seven first randomized trials comparing RT vs. NACT fol-
lowed by RT have been published: Sardi et al.,16 Chang
et al.,25 Benedetti-Pacini,26 Chauvergnet et al.,27 Kumar et al.,28
Leborgne et al.,29 Souhami et al.,30 Sundford et al.,31 Tattersall
et al.,32 Tattersall et al.33 Of these 7 trials, 5 do not show bene-
fits with NACT, 2 demonstrated a significantly better survival
rate with exclusive RT. None compared with CT-RT. The results
of these uncontrolled studies are very difficult to compare with
the results of traditional treatments because they are small
series, with very short follow-up and unclear selection crite-
ria. However, none showed a significant advantage with NACT.
And more than 50% of operated patients received subsequent
RT. This represented a significant morbidity and a substantial
increase in the cost of treatment without significant benefits.
In 2004 a Cochrane Review was published,34 aimed to
assess the effect of NACT followed by RT compared to the
same RT. They report data from 18 trials and 2074 patients
but are unclear if 18 or 15 met the necessary requirements
to be included. Considering these trials together, there was a
high level of statistical heterogeneity, a substantial amount
of which was explained by analyses of trial groups. Both
the external beam RT dose and intracavitary RT dose var-
ied (40–60.8 and 18–80 Gy, respectively), with a total dose in
the range of 55–80 Gy. The author declares that for each of
the outcomes measured, when all trials were combined, a
highly significant level of statistical heterogeneity was evi-
dent, such that it is inappropriate to combine the trials in
this way, which in fact suggests that these trials may not be
addressing exactly the same questions. Considering all trials
together, there was no evidence of an effect of NACT on sur-
vival, or any of the other endpoints. Variation in the duration
of radiotherapy amongst the trials in this meta-analysis could
contribute to the differences seen in local control and survival.
Furthermore, the author suggests that if there is combined
CT and RT cross-resistance, the duration of CT, the delay to
RT and the duration of RT making up the overall treatment
time, could each have an impact on prognosis. Interestingly,
the trials giving more prolonged CT tended to be those with
longer delays to RT and longer durations of RT and vice versa.
However, the control group survival of these two groups of
patients is very similar and within these groups, there is no
evidence that particular types of patients benefit more or less
from CT. Conclusions were: overall results do not support the
use of cisplatin-based NACT prior to RT for women with locally
advanced cervical cancer.
In none of these trials NACT followed by radical radio-
therapy was compared with a concomitant CTRT control arm,
which is not only the standard treatment but the concomitant
CTRT increases survival compared with exclusive RT.
Due to all the data presented and in accordance with the
meta-analyses and the published reviews, adding neoadju-
vant chemotherapy to radiotherapy cannot be recommended
outside the context of clinical trials.
4. Neoadjuvant chemotherapy followed by
surgery versus RT
In 2003, a meta-analysis was published that includes only 5
trials of NACT plus S versus RT.35
The conclusions of this meta-analysis were favorable for
NACT plus S (14% increase in OS at 5 years, from 50% to 64%).
In none of these five trials NACT followed by S was compared
with a CT-RT control arm, which is not only the standard
treatment but the concomitant CT-RT increases the survival
compared with exclusive RT in a similar percentage (≥12%).
Furthermore, in all five trials, RT was suboptimal, either
due to insufficient total dose or due to the prolongation of
treatment time. In one of these trials, 27% of the patients did
not perform brachytherapy, 11% received less than 60 Gy at
point A, and the average dose at point A was 70 Gy whereas
recommended total dose should be 80–90 Gy.
In 2012, a meta-analysis comparing NACT plus S versus
exclusive S was published.14 This meta-analysis includes a
small number of trials, only 5, some of them are very old, with
large variations in the use of adjuvant RT and great disparity
of results,
For a significant percentage of patients assigned to NACT
arms followed by S, S could not be performed due to toxicity
caused by CT or by insufficient response
In the results, the author notes that the number of patients
(872) and events (368) is not large and the results need to be
interpreted with caution. Also, some of the patients included
in these trials would be considered as having localized dis-
ease (FIGO stage IB-IIA) and others would be considered locally
advanced (FIGO stage IB bulky, IIB-IIIB) and, as such, clinically,
they would not often be considered together. This compari-
son is further complicated by the fact that intra-arterial CT
was used in one trial and by the use of postoperative pelvic RT
in the NACT plus S arm. In two trials,36,37 almost all patients
received pelvic RT and in other two trials,25,38 it was given to
around of 30% of patients. The risk factors that determined the
indication of adjuvant RT is not clearly defined in the studies
and differs between them. Therefore, there are a number of
possible confounding factors. Although the HR of 0.65 indi-
cates a 14% absolute overall improvement in 5-year survival,
because baseline survival differs considerably by stage, this
relative benefit translates into absolute improvements ranging
from 8 to 14% at 2 years and 12 to 16% at 5 years. It is note-
worthy that the meta-analysis does not evaluate the impact
of the insufficient total dose of RT administered in some stud-
ies or the impact of the prolongation of the total time of the
radiation treatment while it does on the CT administered. In
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none of these five trials NACT followed by S was compared
with a concomitant CT-RT control arm, which is not only the
standard treatment, but the concomitant CT-RT increases the
survival compared with exclusive RT in a similar percentage
(≥12%).
During the ESMO Congress 2017, published later, a ran-
domized clinical trial comparing NACT followed by S versus
concomitant cisplatin and radiation therapy in patients with
stage IB2, IIA or IIB squamous carcinoma of the cervix was
presented.
635 patients were randomized between both arms, planned
cross-over from NACT-S to CT-RT arm was performed in
patients with unresectable disease after 2 or 3 cycles of CT,
intraoperative inoperability or lymph node positive on frozen
section intraoperative.
DFS at five years in intention-to-treat population was 69.35
in NACT plus S vs. 76.7% in the CTRT arm.
Conclusions of the trial were: RT concurrent with weekly
cisplatin resulted in a higher DFS compared with NACT using
paclitaxel and carboplatin followed by radical surgery in
patients with locally advanced squamous cell cervical cancer.
CT-RT should continue to be the standard of care in locally
advanced cervical cancer.
5. Conclusions
During the last 19 years, CT-RT is generally the primary treat-
ment of choice for stages IB2 to IVA disease based on the
results of 5 randomized clinical trials that have shown that
the use of CT-RT results in a 30% to 50% decrease in the risk of
death compared with RT alone. In 1999 the NCI issued an alert
stating that a strong consideration should be given to using
chemoradiation instead of RT alone. Commonly, platinum
based regimens are used, although a meta-analysis published
in 2008 reported significant benefits with non-platinum-based
agents. This result was confirmed by several trials and a meta-
analysis.
Due to the above, the treatment of CT-RT with platinum
base regimens continues to be the standard for patients with
stage IB2 to IVA of cervical cancer. The NACT should not be
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